Six pharmaceutical companies invested more than 1 billion yuan in R&D in the first three quarters, showing strong innovation momentum

 In recent years, the country has continuously introduced policies to encourage drug innovation, and innovation and development have become the general trend
.
Statistics show that China’s basic research accounted for more than 6% of R&D investment for the first time, and the original innovation capabilities of science and technology and the innovation capabilities of R&D entities have all increased significantly
.
In the pharmaceutical field, the investment of major pharmaceutical companies in research and development is also increasing day by day, their innovation momentum is strong, and research and development capabilities continue to appear
.
Taking the first three quarters of this year as an example, data shows that there are 120 pharmaceutical companies with a total R&D investment of more than 100 million yuan, a year-on-year increase of 33.
33%
.
Among them, six pharmaceutical companies have invested more than 1 billion yuan in R&D in the first three quarters.
The following author will take everyone into these six companies
.
Hengrui Medicine’s R&D investment of 4.
142 billion yuan According to the data of the 2021 third quarter report released by Hengrui Medicine, the R&D investment of Hengrui Medicine continues to increase this year.
The R&D expenditure in the first three quarters of 2021 is as high as 4.
142 billion yuan, a year-on-year increase of 23.
86%
.
R&D expenses in the third quarter alone reached 1.
56 billion yuan, accounting for more than 20% of revenue, setting a record high
.
In terms of innovative drugs, recent information shows that Hengrui’s innovation and development has entered a period of in-depth adjustment: internally, in order to build a strong competitive moat, R&D investment under the innovation-driven strategy is rising; externally, internationalization is to avoid the domestic innovative drug industry It is a beneficial strategy for involution, but it is also inevitable that it will continue to invest in huge amounts
.
At present, Hengrui has 8 innovative drugs on the market in China, more than 50 innovative drugs are under clinical development, more than 240 clinical trials are carried out at home and abroad, and a number of independent intellectual property rights and technology platforms have been built, such as proteolysis Targeted chimera (PROTAC), fully human antibody library and high-throughput antibody discovery, antibody drug conjugates (ADC), T cell engagers, structural biology, etc.
, covering cutting-edge technical fields, forming an echelon Product pipeline
.
Fosun Pharma’s R&D investment of 3.
151 billion yuan According to data from Fosun Pharma’s third quarterly report, Fosun Pharma’s R&D investment in the first three quarters of 2021 totaled 3.
151 billion yuan, a year-on-year increase of 15.
46%
.
Among them, the company's research and development expenses alone reached 2.
414 billion yuan, a year-on-year increase of 28.
54%
.
At present, Fosun Pharma has formed an international R&D layout and strong R&D capabilities.
It has established efficient international R&D teams in China, the United States, India and other places, forming a globally linked R&D system
.
It is reported that the company’s macromolecular drug R&D and commercialization are advancing steadily.
The production line at Xuhui base of slulimumab injection (recombinant anti-PD-1 humanized monoclonal antibody injection) passed the GMP on-site inspection in September 2021.
The drug registration application for the second indication was accepted by the National Food and Drug Administration in September 2021; Trastuzumab for injection was approved for a new 60mg specification, further enriching clinical drug options
.
Mindray Medical’s R&D investment was 1.
629 billion yuan.
According to data from Mindray’s third quarter report, the company’s R&D investment in the first three quarters of 2021 was 1.
79 billion yuan, a year-on-year increase of 19%
.
Under the background of Mindray Medical's continuous focus on independent research and development, the company's ability to launch new products and iterative upgrades continues to improve
.
For example, in the field of life information and support, Mindray Medical has launched a new platform operating bed Hybase V8 (CE), HyPort R80 new suspension bridge I (CE/CFDA), 4K digital operating room (CFDA), single-hole trocar/Hansen puncture New products such as CE and CE
.
In the field of in vitro diagnostics, Mindray Medical has launched new products such as MC-80 automatic cell morphology analyzer, CL-8000i automatic chemiluminescence immunoassay analyzer, and BS-2800M automatic biochemical analyzer
.
In the field of medical imaging, Mindray Medical has mainly launched new products such as the comprehensive ultrasound application solution "Kunlun R7" and the female and child application solution "Nuwa R7"
.
Junshi Biology invested 1.
423 billion yuan in R&D while steadily advancing the progress of various products under research, Junshi Biology continued to enrich and broaden its pipelines.
According to the data of its three-quarter report, the company’s R&D investment in the first three quarters of 2021 totaled 1.
423 billion yuan, a year-on-year increase 17.
56%
.
At present, its R&D pipeline has jumped to 44 items, forming a diversified synergy and complementary product portfolio
.
With its strong independent R&D and innovation capabilities, Junshi Biotech's research pipeline covers the five major areas of tumors and anti-infection.
As the company continues to advance in R&D and commercialization, its layout has gradually improved and its profitability has gradually increased
.
Shanghai Pharmaceuticals R&D Expenses of 1.
367 billion yuan According to data from the third quarter report of Shanghai Pharmaceuticals, in the first three quarters of 2021, Shanghai Pharmaceuticals' R&D expenses reached 1.
367 billion yuan, an increase of 31.
38% year-on-year, and the net profit attributable to the parent after reduction of R&D expenses increased by 26.
04% year-on-year
.
The report shows that Shanghai Pharmaceuticals is accelerating the construction of an innovative drug service platform to provide one-stop management services for upstream and downstream
.
In the first three quarters, the company imported a total of 20 total generation products, and reached in-depth cooperation with many pharmaceutical companies, including Hanhui Pharmaceutical, Bristol-Myers Squibb, and Deqi Pharmaceuticals, to provide partners with clinical trial support.
, Bonded import, national distribution, supply chain optimization and comprehensive solutions including innovative value-added services
.
Kelun Pharmaceutical’s R&D investment is 1.
189 billion yuan.
According to data from Kelun Pharmaceutical’s third quarter report, the company’s R&D investment in the first three quarters of 2021 was 1.
189 billion yuan, an increase of 18.
97% year-on-year
.
Continuous R&D investment has promoted the development of the company's innovative products
.
It is understood that there are 85 research projects in the Kelun Pharmaceutical Innovation Pipeline (38 innovative small molecules, 47 biotech drugs), focusing on tumors, while laying out liver disease, cardiovascular, anesthesia, analgesia, autoimmunity and other disease fields.
, Forming the advantage of product cluster and product iteration
.
Since 2017, Kelun Pharmaceutical has accumulated 89 new products on the market one after another, of which 24 were listed in the first half of this year, 17 were declared for production, and 6-10 new products are expected to be approved in the second half of the year
.